In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster weight loss drug, opening the door for cheaper competing versions.In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster weight loss drug, opening the door for cheaper competing versions. Drugs (Pharmaceuticals), Weight, Obesity, GLP-1 RAs (Drug), Prices (Fares, Fees and Rates), Generic Brands and Products, Regulation and Deregulation of Industry, Ozempic (Drug), Developing Countries, Diabetes, Eli Lilly and Company, Novo Nordisk A/S, Africa, China, Delhi (India), Hong Kong, India, Canada Read More
Ozempic Is About to Go Generic in India, China and Canada
